van Lierop LMA, Devillers MJC, van der Woude CJ, Hoentjen F, et al. Long-term outcomes of increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission: 3-year follow-up of the randomized controlled LADI trial. Gastroenterology 2025 Sep 19:S0016-5085(25)06024.
PMID: 40976380